Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells

[1] Rawla P(2019)Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors Prz Gastroenterol 14 89-103

[2] Sunkara T(2015)Genetics, diagnosis and management of colorectal cancer (review) Oncol Rep 34 1087-96

[3] Barsouk A(2020)Comprehensive review of targeted therapy for colorectal cancer Signal Transduct Target Ther 5 22-309

[4] De Rosa M(2019)A view on drug resistance in cancer Nature 575 299-84

[5] Pace U(2007)Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes Scand J Gastroenterol 42 477-54

[6] Rega D(2004)ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int J Cancer 109 848-32

[7] Costabile V(2008)Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38 Cancer Biol Ther 7 822-76

[8] Duraturo F(2017)Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan Nucleic Acids Res 45 1159-6

[9] Izzo P(2012)Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer Nature 486 532-40

[10] Xie Y-H(2016)Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the wnt signaling pathway Int J Oncol 48 1333-89

[1] Rawla P(2019)Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors Prz Gastroenterol 14 89-103

[2] Sunkara T(2015)Genetics, diagnosis and management of colorectal cancer (review) Oncol Rep 34 1087-96

[3] Barsouk A(2020)Comprehensive review of targeted therapy for colorectal cancer Signal Transduct Target Ther 5 22-309

[4] De Rosa M(2019)A view on drug resistance in cancer Nature 575 299-84

[5] Pace U(2007)Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes Scand J Gastroenterol 42 477-54

[6] Rega D(2004)ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int J Cancer 109 848-32

[7] Costabile V(2008)Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38 Cancer Biol Ther 7 822-76

[8] Duraturo F(2017)Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan Nucleic Acids Res 45 1159-6

[9] Izzo P(2012)Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer Nature 486 532-40

[10] Xie Y-H(2016)Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the wnt signaling pathway Int J Oncol 48 1333-89